Welcome to our dedicated page for Supernus Pharma SEC filings (Ticker: SUPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Supernus Pharmaceuticals, Inc. (SUPN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Supernus is a biopharmaceutical company focused on developing and commercializing products for central nervous system (CNS) diseases, and its filings offer detailed insight into its commercial portfolio, collaborations, and pipeline.
Supernus’s current reports on Form 8-K cover a range of material events. These include announcements of quarterly financial results, where the company reports total revenues, net product sales for CNS therapies such as Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ONAPGO, and other products, as well as royalty, licensing and other revenues and collaboration revenue from ZURZUVAE. Filings also describe non-GAAP measures like adjusted operating earnings and revenues excluding certain legacy products.
Other 8-K filings document corporate transactions, notably the acquisition of Sage Therapeutics, Inc. Supernus details the merger structure, consideration, contingent value rights (CVRs) tied to ZURZUVAE milestones, and the integration of Sage as a wholly owned subsidiary. These filings also outline the collaboration economics with Biogen Inc. related to ZURZUVAE, an oral treatment for postpartum depression.
Additional disclosures address operational updates, such as supply constraints for ONAPGO due to stronger than expected demand and the company’s decision to prioritize existing patients while working to rebuild inventory. Filings also announce upcoming earnings release dates and conference calls, reinforcing the company’s regular reporting cadence.
On Stock Titan, investors can use AI-powered tools to read concise summaries of Supernus’s 8-Ks and other SEC documents, quickly understand key points about CNS product performance, collaboration revenue, acquisitions, and pipeline developments, and identify items such as contingent value rights or other material agreements without manually parsing lengthy filings.
Form 144 filed for Supernus Pharmaceuticals, Inc. (SUPN) reports a proposed sale of 16,587 common shares with an aggregate market value of $763,665.48, representing securities listed on NASDAQ. The filing shows the shares were acquired and paid for on 09/22/2025 through exercise of stock options and paid in cash. The issuer’s outstanding common shares are reported as 56,073,088. The filing also discloses a series of prior 10b5-1 sales by JACK A KHATTAR over the past three months totaling 239,200 shares for gross proceeds of $10,414,682.10. The filer certifies no undisclosed material adverse information and references reliance on Rule 10b5-1 trading instructions where applicable.
Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals, reported option exercise and share sales on 09/08/2025. He exercised 8,074 employee stock options with an exercise price of $25.30 per share (options vesting began 02/24/2018 and expire 02/24/2027), resulting in 8,074 common shares issued. On the same date he sold 6,322 shares at a weighted average price of $46.29 per share (sales occurred at prices between $46.00 and $46.40). Following these transactions he beneficially owned 1,111,983 common shares. The exercise and sale were made pursuant to a 10b5-1 trading plan adopted November 14, 2024.
Insider transactions by Jack A. Khattar, President and CEO of Supernus Pharmaceuticals (SUPN): On 09/05/2025 Mr. Khattar exercised 73,176 employee stock options with a $25.30 exercise price and acquired those shares. The same day he sold 55,578 shares at a weighted average price of $46.01 (sales ranged $46.00–$46.09). After these transactions he beneficially owned 1,110,231 shares directly and 1,005,600 shares indirectly through the KBT Trust. The exercise was reported under a 10b5-1 plan adopted November 14, 2024.
Supernus Pharmaceuticals insider activity notice reports a proposed sale of 6,322 common shares acquired and to be sold on 09/08/2025 following an exercise of stock options. The broker listed is Morgan Stanley Smith Barney LLC and the trade is planned on NASDAQ with an aggregate market value of $290,812. The filing also discloses multiple prior 10b5-1 sales by Jack A Khattar totaling 232,878 shares during Aug–Sep 2025, generating gross proceeds shown in the table. The filer represents no undisclosed material adverse information and certifies compliance with Rule 144 and 10b5-1 representations.
Supernus Pharmaceuticals reported an insider notice to sell common stock following an option exercise. The filer plans to sell 55,578 shares through Morgan Stanley Smith Barney on NASDAQ with an aggregate market value of $2,524,908.54 and an approximate sale date of 09/05/2025. The shares were acquired and paid for in cash on 09/05/2025 via exercise of stock options from the issuer. The filing also discloses multiple 10b5-1 sales by Jack A Khattar in August 2025 totaling 170,300 shares with gross proceeds shown across transactions. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Insider transactions by Jack A. Khattar at Supernus Pharmaceuticals (SUPN) show option exercises and share sales completed under a 10b5-1 plan. On 08/27/2025 and 08/28/2025 Mr. Khattar acquired 17,195 and 38,779 shares by exercising employee stock options at an exercise price of $12.98 per share. He also sold 10,650 shares on 08/27/2025 at a weighted average price of $45.05 and 24,150 shares on 08/28/2025 at a weighted average price of $45.12. After these transactions his direct beneficial ownership is reported at 1,092,633 shares, with an additional 1,005,600 shares indirectly held by the KBT Trust. The Form 4 notes the 10b5-1 trading plan was adopted on November 14, 2024.
Charles W. Newhall III, a director of Supernus Pharmaceuticals, Inc. (SUPN), sold 3,588 shares of the company's common stock on 08/27/2025 under a pre-existing Rule 10b5-1 trading plan. The sales were executed at a weighted average price of $45.01 per share, with transaction prices in the range $45.00 to $45.04. After the reported dispositions, the reporting person beneficially owned 129,644 shares, reported as a direct holding. The filing includes a statement that the reporting person will provide detailed per-price sale quantities on request and notes the 10b5-1 plan was adopted March 3, 2025.
Supernus Pharmaceuticals (SUPN) Form 144 notice reports an intended sale of 24,150 common shares through Morgan Stanley Smith Barney with an aggregate market value of $1,088,440.50, based on approximately 56,073,088 shares outstanding. The filing lists the approximate sale date as 08/28/2025.
The securities were acquired and are being sold on 08/28/2025 following the exercise of stock options, with payment in cash to the issuer. The filing also discloses multiple recent Rule 10b5-1 sales by Jack A. Khattar in August 2025 totaling sizable share amounts and gross proceeds across several dates, indicating ongoing disposition of shares by this insider.
Padmanabh P. Bhatt, Senior Vice President of IP and Chief Scientific Officer at Supernus Pharmaceuticals (SUPN), reported equity transactions dated 08/25/2025. The report shows the settlement of 1,250 shares upon vesting of Performance Share Units awarded on February 23, 2023, and 581 shares were withheld by the company to satisfy tax withholding at an indicated price of $41.46 per share. Following these transactions, the reporting person beneficially owned 13,718 shares of common stock. The filing explains the PSUs vested after achievement of individual performance objectives established June 12, 2023. The form was signed by an attorney-in-fact on behalf of the reporting person on 08/27/2025.
Frank Mottola, SVP, Quality, GMP, Ops, IT at Supernus Pharmaceuticals (SUPN), reported option exercise and an immediate sale on 08/25/2025. He exercised an employee stock option with a $12.98 exercise price to acquire 14,000 shares and simultaneously sold 14,000 shares at $44.51.
After these transactions the filing shows the Reporting Person beneficially owned 29,496 shares (which includes 345 shares from the company Employee Stock Purchase Plan). The filing also notes the exercised option vests in four equal annual installments beginning March 1, 2017, and that the underlying shares were sold prior to option expiration on March 1, 2026.